Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Swedish Orphan Biovitrum and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Swedish Orphan Biovitrum	20.67%	17.92%	9.30%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Analyst Ratings

This is a breakdown of current ratings and price targets for Swedish Orphan Biovitrum and BioCryst Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Swedish Orphan Biovitrum	0	3	5	0	2.62
BioCryst Pharmaceuticals	1	4	6	0	2.45

BioCryst Pharmaceuticals has a consensus target price of $19.44, indicating a potential upside of 129.57%. Given BioCryst Pharmaceuticals’ higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Swedish Orphan Biovitrum.

Earnings & Valuation

This table compares Swedish Orphan Biovitrum and BioCryst Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Swedish Orphan Biovitrum	$2.89 billion	5.64	$48.85 million	$2.01	22.74
BioCryst Pharmaceuticals	$874.84 million	2.47	$263.86 million	($1.50)	-5.65

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Swedish Orphan Biovitrum. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Swedish Orphan Biovitrum has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.